Related references
Note: Only part of the references are listed.Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
Christophe Schmitt et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
Michael U. Callaghan et al.
BLOOD (2021)
Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor
Carla Valsecchi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
Fredrik Jonsson et al.
CLINICAL PHARMACOKINETICS (2021)
Population Pharmacokinetic Analysis and Exploratory Exposure-Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
Sylvie Retout et al.
CLINICAL PHARMACOKINETICS (2020)
WFH Guidelines for the Management of Hemophilia, 3rd edition
Alok Srivastava et al.
HAEMOPHILIA (2020)
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
Steven W. Pipe et al.
LANCET HAEMATOLOGY (2019)
A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors
Midori Shima et al.
HAEMOPHILIA (2019)
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
Guy Young et al.
BLOOD (2019)
Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee
P. W. Collins et al.
HAEMOPHILIA (2018)
In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents
R. Hartmann et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
J. Mahlangu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Practical aspects of extended half-life products for the treatment of haemophilia
Thierry Lambert et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2018)
Immunogenicity of biologics in inflammatory bowel disease
Severine Vermeire et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2018)
Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies
Ido Paz-Priel et al.
BLOOD (2018)
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A
Koichiro Yoneyama et al.
CLINICAL PHARMACOKINETICS (2018)
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
Emilie M. J. van Brummelen et al.
ONCOLOGIST (2016)
The current status of prophylactic replacement therapy in children and adults with haemophilia
Rolf Ljung et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Proposal for a harmonized descriptive analyte nomenclature for quantitative large-molecule bioanalysis
Julia Heinrich et al.
BIOANALYSIS (2015)
Hemophilia A in the third millennium
Massimo Franchini et al.
BLOOD REVIEWS (2013)
Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
C. C. Mok et al.
CLINICAL RHEUMATOLOGY (2013)
Factor VIII inhibitors in hemophilia A: rationale and latest evidence
Char Witmer et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)
Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
Narendra Chirmule et al.
AAPS JOURNAL (2012)
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
Takehisa Kitazawa et al.
NATURE MEDICINE (2012)
Inhibitors in haemophilia: pathophysiology
JMR Saint-Remy et al.
HAEMOPHILIA (2004)
Medical progress - The hemophilias - From royal genes to gene therapy
PM Mannucci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
